Product Type and the Risk of Inhibitor Development in Nonsevere Haemophilia a Patients: A Case-Control Study

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.16490
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

HLA-DRB1–factor VIII Binding Is a Risk Factor for Inhibitor Development in Nonsevere Hemophilia: A Case-Control Study

Blood advances
Hematology
2018English

An Update on the ‘Danger Theory‘ in Inhibitor Development in Haemophilia A

Expert Review of Hematology
Hematology
2019English

In Non-Severe Hemophilia a the Risk of Inhibitor After Intensive Factor Treatment Is Greater in Older Patients: A Case-Control Study

Journal of Thrombosis and Haemostasis
MedicineHematology
2010English

Inhibitor Development in Non-Severe Haemophilia Across Europe

Thrombosis and Haemostasis
Hematology
2015English

Psy223 - Qualitative Research in Haemophilia A: Emicizumab Transforms Lifestyle of Patients With Inhibitor

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Acute Abdomen in a Patient With Haemophilia A: A Case Study

International Archives of Medicine
2015English

Study of Serum Magnesium Levels in Type I Diabetes Mellitus Patients: A Case Control Study

Pediatric Review: International Journal of Pediatric Research
2019English

Risk Management in Medical Product Development Process Using Traditional FMEA and Fuzzy Linguistic Approach: A Case Study

Journal of Industrial Engineering International
IndustrialManufacturing Engineering
2015English

Reconfirmation of Newly Discovered Risk Factors of Diabetic Peripheral Neuropathy in Patients With Type 2 Diabetes: A Case-Control Study

PLoS ONE
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy